{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:48:47Z","timestamp":1787590127737,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.4103\/sjg.sjg_355_25","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:00:06Z","timestamp":1764223206000},"page":"22-32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and safety of upadacitinib in refractory pediatric inflammatory bowel disease: A single-arm meta-analysis of observational studies"],"prefix":"10.4103","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1424-5784","authenticated-orcid":false,"given":"Ahmed A.","family":"Al Sarkhy","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Gastroenterology Unit, College of Medicine, King Saud University, Riyadh, Saudi Arabia"},{"name":"Celiac Disease Research Chair, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6768-6129","authenticated-orcid":false,"given":"Alhanouf A.","family":"AlZahrani","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-8566","authenticated-orcid":false,"given":"Afnan A.","family":"AlSunaidi","sequence":"additional","affiliation":[{"name":"Pharmacy Department, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"R1-20260108","first-page":"423","article-title":"Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends: Inflamm Bowel Dis","volume":"17","author":"Benchimol","year":"2011"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mcna.2009.10.002","article-title":"Pediatric inflammatory bowel disease: Highlighting pediatric differences in IBD","volume":"94","author":"Sauer","year":"2010","journal-title":"Med Clin North Am"},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","article-title":"The Medical management of paediatric Crohn's Disease: An ECCO-ESPGHAN guideline update","volume":"15","author":"van Rheenen","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn's disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"key":"R6-20260108","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"111229","DOI":"10.1016\/j.intimp.2023.111229","article-title":"Effectiveness and safety of upadacitinib for inflammatory bowel disease: A systematic review and meta-analysis of RCT and real-world observational studies","volume":"126","author":"Zheng","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/apt.70016","article-title":"Upadacitinib for induction of remission in paediatric Crohn's Disease: An International multicentre retrospective study","volume":"61","author":"Cohen","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"jjae182","DOI":"10.1093\/ecco-jcc\/jjae182","article-title":"Upadacitinib for induction of remission in pediatric ulcerative colitis: An International multicenter study","volume":"19","author":"Yerushalmy-Feler","year":"2025","journal-title":"J Crohns Colitis"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: Analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"},{"key":"R11-20260108","article-title":"Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective","author":"He","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/ibd\/izad300","article-title":"Single-center experience with upadacitinib for adolescents with refractory inflammatory bowel disease","volume":"30","author":"Spencer","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jpn3.12408","article-title":"Upadacitinib is associated with clinical response and steroid-free remission for children and adolescents with inflammatory bowel disease","volume":"80","author":"Runde","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/jpn3.70024","article-title":"Observation of the efficacy of upadacitinib as salvage therapy for refractory pediatric inflammatory bowel disease","volume":"80","author":"Mei","year":"2025","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"R16-20260108","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"e64016","DOI":"10.2196\/64016","article-title":"MetaAnalysisOnline.com: Web-based tool for the rapid meta-analysis of clinical and epidemiological studies","volume":"27","author":"Fekete","year":"2025","journal-title":"J Med Internet Res"},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib Is effective and safe in both ulcerative Colitis and Crohn's Disease: Prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/flgastro-2024-102668","article-title":"Real-world effectiveness of upadacitinib in Crohn's disease: A UK multicentre retrospective cohort study","volume":"15","author":"Elford","year":"2024","journal-title":"Frontline Gastroenterol"},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicentre real-world experience of upadacitinib in the treatment of Crohn's Disease","volume":"17","author":"Chugh","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/ibd\/izaa277","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","volume":"27","author":"Dolinger","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: A systematic review and meta-analysis","volume":"20","author":"Ahmed","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"(Supplement_1)","key":"R27-20260108","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1093\/ibd\/izae020.193","article-title":"Systematic review with meta-analysis: Safety and effictiveness of combining biologics and small molecules in inflmammatory bowel disease","volume":"30","author":"Osman","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/children12010075","article-title":"Dual biologic or small molecule therapy in pediatric inflammatory bowel disease: A single center experience","volume":"12","author":"Guo","year":"2025","journal-title":"Children"},{"key":"R29-20260108","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s10620-024-08379-9","article-title":"Real-world outcomes of dual advanced therapy in children and young adults with inflammatory bowel disease","volume":"69","author":"Kellar","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/ibd\/izad064","article-title":"Dual biologic or small molecule therapy in refractory pediatric inflammatory bowel disease (DOUBLE-PIBD): A multicenter study from the pediatric IBD Porto Group of ESPGHAN","volume":"30","author":"Yerushalmy-Feler","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: Analysis of the measure Up 1, measure Up 2, and AD Up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"key":"R32-20260108","article-title":"Janus Kinase (JAK) Inhibitor-Induced Acne in Inflammatory Bowel Disease: An International, Multicenter, Retrospective Cohort Study","author":"Honap","journal-title":"Clin Gastroenterol Hepatol. 2025 Jun 11"},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"6894","DOI":"10.3390\/jcm11236894","article-title":"The effect of upadacitinib on lipid profile and cardiovascular events: A meta-analysis of randomized controlled trials","volume":"11","author":"Makris","year":"2022","journal-title":"J Clin Med"},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"1241954","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: A systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s10096-021-04298-z","article-title":"The impact of varicella vaccination on paediatric herpes zoster epidemiology: A Canadian population-based retrospective cohort study","volume":"40","author":"Rafferty","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"(Supplement_4)","key":"R36-20260108","doi-asserted-by":"crossref","first-page":"S387","DOI":"10.1093\/infdis\/jiaa573","article-title":"Live Attenuated varicella vaccine: Prevention of varicella and of zoster","volume":"224","author":"Gershon","year":"2021","journal-title":"J Infect Dis"},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_355_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:39Z","timestamp":1787067999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_355_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_355_25","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"2025-09-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}